Specific gapmer-based ASOs, called G3139 and RX-020, have been devised against Bcl2 and Akt-1 mRNAs, respectively, and tested in pre-clinical and clinical studies for NSCLC therapy. This evidence concerns the gene BCL2 and non-small cell lung carcinoma.